WT1 encodes a tumor suppressor that is expressed in cells of the developing kidney and is inactivated in Wilms tumor, a pediatric kidney cancer. The adenovirus E1B 55K gene product contributes to the transformation of primary baby rat kidney (BRK) cells by binding and inactivating the product of the p53 tumor suppressor. We have previously demonstrated that WT1 and p53 are present within a protein complex in vivo. We now show that WT1 is physically associated with E1B 55K in adenovirus-transformed cells, an interaction that is mediated by the ®rst two zinc ®ngers of WT1. Immunodepletion of p53 abrogates the coimmunoprecipitation of E1B 55K and WT1, consistent with the presence of a trimeric protein complex containing these three proteins. In the presence of E1B 55K, WT1 which is normally localized in the nucleus, is retained within a very high molecular weight complex and sequestered in the characteristic perinuclear cytoplasmic body that contains E1B 55K and p53. Expression of E1B 55K in osteosarcoma cells that undergo apoptosis following expression of WT1 inhibits WT1-mediated cell death. We conclude that E1B 55K may target WT1 along with p53, resulting in the functional inactivation of both tumor suppressor gene products by this viral oncoprotein.
WT1 encodes a tumor suppressor that is expressed in cells of the developing kidney and is inactivated in Wilms tumor, a pediatric kidney cancer. The adenovirus E1B 55K gene product contributes to the transformation of primary baby rat kidney (BRK) cells by binding and inactivating the product of the p53 tumor suppressor. We have previously demonstrated that WT1 and p53 are present within a protein complex in vivo. We now show that WT1 is physically associated with E1B 55K in adenovirus-transformed cells, an interaction that is mediated by the ®rst two zinc ®ngers of WT1. Immunodepletion of p53 abrogates the coimmunoprecipitation of E1B 55K and WT1, consistent with the presence of a trimeric protein complex containing these three proteins. In the presence of E1B 55K, WT1 which is normally localized in the nucleus, is retained within a very high molecular weight complex and sequestered in the characteristic perinuclear cytoplasmic body that contains E1B 55K and p53. Expression of E1B 55K in osteosarcoma cells that undergo apoptosis following expression of WT1 inhibits WT1-mediated cell death.
Introduction
The tumor suppressor gene WT1 is inactivated in a subset of Wilms tumors and in the germline of children predisposed to this pediatric kidney cancer (see Hastie, 1995) . WT1 is normally expressed in tissues that undergo mesothelial to epithelial transition, most prominently in the kidney, where it is transiently expressed in developing glomeruli (Pritchard-Jones et al., 1990) . Homozygous inactivation of wt1 in the mouse germline results in a complete failure of renal development, consistent with a critical role in organogenesis (Kreidberg et al., 1993) . WT1 protein has properties of a transcription factor, with four Cterminal zinc ®ngers confering DNA binding activity and a proline-rich transactivation domain at the Nterminus (Call et al., 1990; Gessler et al., 1990) . In transient transfection assays, WT1 demonstrates binding to GC-rich promoters, followed by transcriptional repression (Rauscher III F, 1993) . However, the physiological function of WT1 appears to be complex. Reintroduction of WT1 into Wilms tumor cells inhibits growth, and inducible expression in osteosarcoma cells triggers apoptosis Englert et al., 1995) . This eect is dependent upon transcriptional repression of the epidermal growth factor receptor (EGFR) gene, suggesting that it results from the withdrawal of growth factor-mediated survival signals. In contrast, induction of WT1 expression at levels below those required to suppress EGFR synthesis modulates the function of p53, a protein with which WT1 forms a physical complex in vivo . Expression of WT1 at low levels inhibits the p53-mediated apoptosis that is triggered by ionizing radiation or by expression of adenovirus E1A. This anti-apoptotic function of WT1 is consistent with the observation that renal blastemal cells, which normally express low levels of WT1, demonstrate widespread apoptosis in WT1-null mice (Kreidberg et al., 1993) .
The transforming genes encoded by the E1 region of adenovirus have provided a paradigm for the ability of viral oncogenes to target host tumor suppressor genes (Stillman, 1986; Jones, 1990) . Adenovirus E1A binds to the so-called pocket proteins, RB, p107 and p130, resulting in their dissociation from E2F transcription factors and in the stimulation of cell cycle progression. In primary BRK cells expressing wild-type p53, this aberrant proliferation signal is accompanied by the induction of apoptosis, explaining the requirement for both E1A and E1B to achieve cellular transformation (Debbas and White, 1993) . E1B encodes two proteins, both of which inhibit p53-induced cell death. E1B 19K modulates p53-mediated transactivation and binds to the apoptosis-inducing protein Bak (Sabbatini et al., 1995; Farrow et al., 1995) . E1B 55K binds directly to p53 and inhibits its transactivational properties (Sarnow et al., 1982; Yew and Berk, 1992; Yew et al., 1994) . The mechanism underlying the eect of E1B 55K may be complex. In kidney cells transformed by adenovirus serotype 5, most of the cellular E1B 55K and p53 proteins are localized to a single perinuclear cytoplasmic body, suggesting that physical sequestration of p53 contributes to its inactivation (Zantema et al., 1985a) . In addition, E1B 55K contains a transcriptional repressor domain that acts to suppress p53-mediated transcriptional activation (Yew and Berk, 1992; Yew et al., 1994) .
BRK cells used in adenovirus-transformation assays are derived from 5 day old rat kidneys, a time of peak glomerular dierentiation (van der Eb and Graham, 1980) . In these primary cell transformation experiments, transfection of a dominant-negative WT1 mutant cooperates with adenovirus E1A to produce foci (Haber et al., 1992) , whereas wild-type WT1 reduces the number of transformed foci induced by cotransfection of E1A and E1B (SM and DH, unpublished) . Furthermore, dierent WT1 isoforms appear to either enhance or suppress the in vivo growth properties of established adenovirus-transformed BRK cell lines (Menke et al., 1996) . We now show that WT1 is physically associated with E1B 55K in adenovirustransformed kidney cells. WT1 is present, along with p53 and E1B 55K, within a high molecular weight complex and localized in a cytoplasmic body. Together with the observation that E1B 55K abrogates WT1-mediated apoptosis, these results suggest that WT1 constitutes a cellular target for this transforming viral oncoprotein.
Results

Coimmunoprecipitation of E1B 55K and WT1 in adenovirus-transformed kidney cells
In testing the role of WT1 in the primary BRK cell transformation assay, we established cell lines transfected with E1A and E1B (10.2 cells) or E1A alone (6.1 cells) (Haber et al., 1992) . The endogenous WT1 transcript in these cells is wild-type, demonstrated by nucleotide sequencing of RT ± PCR products (data not shown), and native WT1 protein is expressed at low levels, detectable by immunoprecipitation of metabolically labeled lysates. Extraction of 10.2 cellular lysate using non-ionic detergent conditions, followed by immunoprecipitation using antibody WTc8 directed against the N terminus of WT1, resulted in coprecipitation of bands that were not observed following immunoprecipitation with pre-immune serum ( Figure  1a) . A band of *55kD comigrated with authentic E1B 55K immunoprecipitated either directly or through its S-methionine-labeled proteins were analysed. (c) Immunoprecipitation of 6.1 and 10.2 cellular lysates using anti-p53 antibody or the mouse monoclonal antibody DG10 against WT1. Equal amounts of radiolabeled proteins were analysed. To better visualize bands immunoprecipitated with antibody DG10, the exposure time was three times longer than that required for the antip53 antibody PAb122 known interaction with p53 ( Figure 1b) . This band was coprecipitated with WT1 from 10.2 cells, but not from 6.1 cells lacking E1B 55K, suggesting that it may represent E1B 55K itself. Coprecipitation of WT1 and putative E1B 55K from 10.2 cells but not from 6.1 cells was also observed using the monoclonal antibody DG10, directed against the middle third of WT1 (Figure 1c) , as well as with epitope-tagged WT1, indicating that it did not result from coincidental cross-reactivity by a speci®c antibody. The ecient metabolic labeling and distinct migration position of E1B 55K make it readily apparent in these coimmunoprecipitation experiments, in contrast to p53, whose slow turnover in cells expressing E1B 55K and comigration with WT1 hinders detection. The interaction between WT1 and the putative E1B 55K was lost upon extraction of proteins using stringent buer conditions (26RIPA buer), consistent with a protein-protein interaction (data not shown).
Western blotting was used to con®rm the identity of the WT1-associated protein as E1B 55K. Two dierent antibodies directed against WT1, rabbit polyclonal antibody WTc8 and mouse monoclonal antibody WT56, were covalently crosslinked to protein A-or protein G-Sepharose respectively and used to immunoprecipitate unlabeled cellular extracts, followed by immunoblotting analysis with antibody against E1B 55K. Coprecipitation of E1B 55K with WT1 was evident in 10.2 cells and absent in 6.1 cells (Figure 2a , b). E1B 55K was not immunoprecipitated from 10.2 cellular lysates using nonspeci®c antibodies, con®rming the speci®city of this coprecipitation (Figure 2c ).
To determine whether the coprecipitation of E1B 55K with WT1 was evident in another cell type, we analysed 293 cells, an adenovirus-transformed human kidney cell line expressing low levels of endogenous WT1. Immunoprecipitation-Western analysis also demonstrated coprecipitation of E1B 55K with WT1 in these cells ( Figure 2d ). As expected for an in vivo protein interaction, coprecipitation of E1B 55K with WT1 was dependent upon extraction conditions. Extraction of cellular lysates using high salt and non-ionic detergent conditions (400 mM NaCl and 1% Nonidet P40) readily demonstrated coprecipitation of these two proteins, while addition of an ionic detergent (0.5% deoxycholate) greatly reduced this interaction ( Figure 2d ). Figure 2 E1B 55K is coimmunoprecipitated with WT1 from adenovirus-transformed cells. Immunoprecipitation-Western analysis of cellular lysates from BRK cells expressing E1A (6.1 cells) or E1A and E1B (10.2 cells). Equal amounts of lysates (1 mg) were immunoprecipitated using the polyclonal anti-WT1 antibody WTc8 (a) or the monoclonal antibody WT56 (b), followed by immunoblotting analysis using an antibody against E1B 55K. Direct Western blotting of cellular lysates (100 mg) is shown to demonstrate the migration position of E1B 55K. M is a mock immunoprecipitation to demonstrate the absence of cross-reactivity of the HRP-conjugated 28 antibody to the immunoglobulin heavy chain used in the immunoprecipitation. (c) E1B 55K-immunoblot of 10.2 cellular lysates (1 mg) immunoprecipitated either with antibody WTc8 or with a nonspeci®c antibody (directed against p27) to demonstrate the absence of coprecipitation of E1B 55K. 100 mg of lysate was analysed directly to demonstrate the migration position of E1B 55K. (d) E1B 55K-immunoblot of anti-WT1 immunoprecipitates from 293 cells, an adenovirus-transformed human kidney cell line. Coprecipitation of E1B 55K with WT1 was observed following extraction of cellular lysates (1 mg) using high salt and nonionic detergent conditions, but it was greatly reduced by addition of the ionic detergent deoxycholate (0.5% DOC), consistent with a protein interaction (compare lanes 2 and 4). Direct E1B-immunoblot analysis of cellular lysates (100 mg) is shown to demonstrate the migration position of E1B 55K and comparable extraction of under the two buer conditions (compare lanes 1 and 3)
Interaction of E1B 55K with WT1 zinc ®ngers 1 ± 2 and formation of a trimeric complex with p53
To determine the domain of WT1 required for its coprecipitation with E1B 55K, we generated stably transfected 10.2 subclones, expressing WT1-deletion constructs tagged with the HA epitope. Comparable expression of all the deletion constructs is shown by Western blot analysis using the 12CA5 antibody directed against the HA epitope ( Figure 3b ). Coimmunoprecipitation of E1B 55K was observed with tagged WT1 proteins containing a deletion in the transactivation domain or spanning zinc ®ngers 3 ± 4. However, it was reduced by deletion of WT1 zinc ®ngers 2 ± 3 and abolished by deletion of zinc ®ngers 1 ± 2 (Figure 3a,c) . Identi®cation of the WT1 zinc ®nger domain as the site required for interaction with E1B 55K explains the inability of an antibody directed against the C terminus of WT1 (antibody C19, Santa Cruz) to detect this protein interaction, presumably due to steric inhibition (data not shown). The observation that zinc ®ngers 1 ± 2 of WT1 are required for this interaction is particularly interesting, since the same domain is required for the interaction between WT1 and p53 . It is therefore possible that WT1 binds exclusively with either p53 or with E1B 55K. Alternatively, given the known interaction between p53 and E1B 55K, these results raise the possibility of a trimeric protein complex, consisting of WT1, p53 and E1B 55K.
To determine whether p53 is part of the protein complex with WT1 and E1B 55K, we undertook p53-immunodepletion experiments. Extracts of 10.2 cells were precleared with a mixture of monoclonal antibodies against p53, leading to the removal of all detectable cellular p53 (Figure 4a ). The p53-immunodepleted lysate retained detectable E1B 55K, indicating that only a fraction of E1B 55K was associated with p53 ( Figure 4b ). However, anti-WT1 immunoprecipitation of the p53-depleted lysate no longer resulted in the coimmunoprecipitation of E1B 55K (Figure 4b ). This observation indicates that the association of E1B 55K Formation of a high molecular weight complex containing WT1, p53 and E1B 55K
To determine the size of the protein complex containing WT1, p53 and E1B 55K, we resolved cellular lysates by gel ®ltration chromatography and analysed column fractions by immunoblotting using antibodies against the three proteins. Figure 5 shows the analysis of 10.2 cells expressing comparable levels of stably transfected HA-tagged WT1 expression constructs, either lacking the p53-E1B 55K interaction domain or with an adjacent deletion that does not aect this protein interaction. As expected, both p53 and E1B 55K migrated in a high molecular weight complex, ranging from 200 kD to 4900 kD, with most of these proteins present within the 5900 kD fractions. WT1 protein with a preserved p53-E1B 55K interacting domain (D363 ± 450) was found virtually exclusively in fractions 5900 kD (Figure 5a ). In contrast, WT1 protein with a deletion that disrupts the p53-E1B 55K interaction (D333 ± 392) migrated in a smaller molecular weight complex of 200 ± 350 kD, consistent with the position of wild-type WT1 in the absence of E1B 55K . These observations indicate that in adenovirus-transformed cells, WT1, p53 and E1B 55K are present within a very high Immunoprecipitation-Western analysis of 10.2 cellular lysates following p53-immunodepletion. Equal amounts of 10.2 lysate (500 mg) or p53-immunodepleted lysate were immunoprecipitated using anti-WT1 antibody WTc8, followed by immunoblotting analysis with anti-E1B 55K antibody. Cellular lysate (100 mg) was also analysed directly by immunoblotting to demonstrate the migration position of E1B 55K, and an equal amount of p53-depleted lysate was analysed directly to con®rm the presence of residual E1B 55K following depletion of p53 Sequestration of WT1 by E1B 55K S Maheswaran et al molecular weight protein complex. Presence of WT1 within this complex requires the WT1 zinc ®ngers 1-2 domain, required for its interaction with both p53 and E1B 55K, and it appears to be quantitative, with all detectable cellular WT1 migrating at the high molecular weight.
Colocalization of WT1, p53 and E1B 55K within a cytoplasmic body
Transformation of cells with adenovirus 5 is associated with the formation of a characteristic cytoplasmic body, containing E1B 55K and p53, along with micro®laments (Zantema et al., 1985a) . To determine the cellular localization of the WT1 complex in 10.2 cells, we analysed these cells by immuno¯uorescence using antibodies against WT1, p53, and E1B 55K. Antibody speci®city was con®rmed by staining BRK cells expressing a temperature sensitive p53 allele (tsp53) or with a tetracycline-regulated WT1 construct (Figure 6a ). Anti-p53 antibody PAb 122 detected a nuclear pattern in BRK tsp53 cells following growth at 328C and a cytoplasmic pattern following growth at 398C, when the protein is in the mutant conformation (Michalovitz et al., 1990) . This temperature shift has no eect on staining with anti-WT1 antibody WTc8, con®rming the absence of cross-reactivity with p53. BRK cells with tetracycline-regulated WT1 expression showed faint nuclear staining with WTc8 in the presence of tetracycline, and high levels of staining following withdrawal of tetracycline. Pre-immune serum showed no detectable signal in the absence of tetracycline (Figure 6a ). Analysis of 10.2 cells by dual staining with anti-p53 (¯uorescein) and anti-E1B 55K (rhodamine) antibodies demonstrated the characteristic single cytoplasmic body containing both of these proteins (Figure 6b ). Staining of these cells with anti-WT1 (¯uorescein) and anti-E1B 55K (rhodamine) antibodies showed similar colocalization of these two proteins, as did co-staining with anti-WT1 (¯uorescein) and anti-p53 antibodies (rhodamine) (Figure 6b ). The cytoplasmic localization of each of these proteins was apparent following individual staining with each antibody, con®rming that it did not result from contamination of dual immuno¯uorescence signals (data not shown). Similar co-localization of WT1, p53 and E1B 55K was observed in 293 cells, although the cytoplasmic body in these human adenovirus-transformed cells was less well demarcated than in rodent cells (data not shown). Localization of WT1 in the cytoplasmic body was evident using two polyclonal antibodies raised against the N-terminus of WT1, WTc7 and WTc8 (data not shown). The cytoplasmic body was not detected using the C-19 antibody (Santa Cruz) which recognizes the C-terminus of WT1, consistent with potential steric inhibition, or using monoclonal antibody WT56, presumably because of its lower sensitivity in immuno¯uorescence analysis.
To con®rm the precise colocalization of WT1 and E1B 55K, 10.2 cells stained with¯uorescein-conjugated anti-WT1 and rhodamine-conjugated anti-E1B 55K antibodies were analysed by confocal imaging. Colocalization of these two proteins in the perinuclear body is demonstrated (Figure 6c ). Of interest, WT1 staining appears in the center of the cytoplasmic body, where it co-localized with E1B 55K. However, the adenoviral protein also extended to the periphery of the cytoplasmic body, a region that appeared free of WT1, as demonstrated by the red rim in the merged confocal image (Figure 6c ). This may result from the higher levels of E1B 55K expression in these cells, compared with WT1, or from a compartmentalization within this poorly understood cellular structure. 
Abrogation of WT1-mediated apoptosis by E1B 55K
The apparent sequestration of WT1 within a cytoplasmic body containing p53 and E1B 55K suggests that its function is likely to be compromised by this protein association. The function of WT1 as a tumor suppressor is most clearly demonstrated in U2OS osteosarcoma cells, which undergo apoptosis following expression of the WT1(7KTS) isoform . We therefore compared the eect of WT1 in U2OS stably expressing E1B 55K and in parental U2OS cells. As expected, cotransfection of U2OS cells with CMV-driven WT1(7KTS) and a plasmid encoding hygromycin resistance, resulted in marked suppression of drug-resistant colonies, compared with the empty CMV vector. In contrast, U2OS cells stably transfected with E1B 55K were resistant to WT1-mediated growth inhibition (Figure 7a ). To ensure that this protective eect was not restricted to an individual U2OS cell line expressing E1B 55K, we cotransfected parental U2OS cells with a hygromycin-resistance construct, along with CMV-driven WT1(7KTS), E1B 55K, or WT1(7KTS) plus E1B 55K. As expected, transfection of WT1 alone resulted in marked suppression of colony formation. Transfection of CMV-driven E1B 55K led to a moderate reduction in colony numbers, compared with vector alone, consistent with a toxic eect of this viral oncoprotein expressed at high levels. However, cotransfection of E1B 55K and WT1(7KTS) resulted in inhibition of WT1-mediated growth suppression (Figure 7b ).
Discussion
We have shown that the E1B 55K protein is associated with the WT1 gene product in adenovirus-transformed kidney cells. This protein interaction is observed in both rodent BRK cells and in human 293 cells, and its speci®city is con®rmed by the use of multiple antibodies to dierent WT1 epitopes as well as tagged WT1 constructs. The interaction between WT1 and E1B 55K also appears to involve p53, which interacts with both of these proteins, suggesting the formation of a trimeric complex. This protein association itself is part of a higher order complex, consistent with the aggregation of E1B 55K within a characteristic cytoplasmic body. The ability of E1B 55K to cause sequestration of WT1 within this cytoplasmic structure is consistent with its suppression of WT1-mediated growth inhibition. These observations suggest that adenovirus 5 E1B 55K, a potent transforming oncoprotein in primary kidney cells, may target WT1 along with p53.
The coimmunoprecipitation of E1B 55K and WT1 in adenovirus-transformed kidney cells is particularly interesting, given the physical interaction between WT1 and p53 which is evident in BRK cells . Demonstrating coimmunoprecipitation of E1B 55K and WT1 is facilitated by the ecient metabolic labeling and distinct migration position of E1B 55K, whereas p53 comigrates with WT1 and has a slow turnover in the presence of E1B 55K. However, our data suggest the presence of a trimeric complex containing these three proteins. This is based upon immunodepletion experiments indicating that removal of cellular p53 abrogates the coimmunoprecipitation of E1B 55K and WT1, and on gel ®ltration experiments demonstrating presence of these three proteins within a high molecular weight complex. Zinc ®ngers 1 ± 2 of WT1 are required for its interaction with E1B 55K: BRK cells expressing epitope-tagged WT1 lacking this domain fail to show its coimmunoprecipitation with E1B 55K or its presence within the high molecular weight complex. The fact that this WT1 domain is identical to that required for the interaction between WT1 and p53 raises the possibility that WT1 may not bind E1B 55K directly, but rather that it binds to p53, which in turn interacts with E1B 55K. We have been unable to test this directly using Saos-2 cells, which have a homozygous deletion of p53, since these cells do not tolerate expression of E1B 55K (SM and DH, unpublished) . Mutant p53 shows preserved binding to E1B 55K and attempts at overexpressing it in adenovirus-transformed BRK cells have also been unsuccessful (E White, personal communication) . Demonstrating the precise composition of the trimeric complex containing WT1, p53 and E1B 55K will therefore require reconstitution of this protein association in vitro.
The coimmunoprecipitation of WT1 and E1B 55K is not shared by other cellular and viral oncogene products known to bind p53. We have not observed coprecipitation of E1B 55K and the cellular protein MDM2, which is known to bind p53, nor is WT1 coprecipitated with SV40 T antigen, another viral oncoprotein that targets p53 (data not shown). This dierence may result in part from dierent domains within p53 that are bound by these proteins. Both E1B 55K and MDM2 bind to the N terminus of p53 (Kao et al., 1990; Chen et al., 1993; Oliner et al., 1993) , making a trimeric complex unlikely. On the other hand, SV40 T antigen interacts with the middle portion of p53 (Tan et al., 1986; Jenkins et al., 1988) , which may interfere with the domain required for binding to WT1. While we have de®ned the WT1 domain involved in binding to p53 and E1B 55K, further work will be required to map the corresponding domains within p53 and E1B 55K. This is complicated by the fact that the association of WT1 and E1B 55K, like that between WT1 and p53 , is not readily detectable in vitro. In this context, it is of interest that E1B 55K and p53 also do not interact in vitro, and demonstration of that protein association requires analysis of cells stably expressing these proteins (Braithwait and Jenkins, 1989) . However, mixing experiments have suggested that the combination of in vitro translated p53 and in vivo synthesized E1B 55K does result in the association of these two proteins, consistent with the need for in vivo protein modification or the presence of additional stabilizing factors (Braithwait and Jenkins, 1989) .
The appparent aggregation of E1B 55K into higher order complexes within the cytoplasmic body may also contribute to the stabilization of its interactions with both p53 and WT1. This apparent sequestration within a single cytoplasmic structure is a striking feature of the physical association between E1B 55K and host cell proteins, providing a dramatic illustration of the ability of a viral oncoprotein to inactivate a tumor suppressor gene product (Zantema et al., 1985a) . Formation of this cellular structure has been observed with adenovirus serotype 5, whose E1B 55K protein binds p53, but not with serotype 12, whose corresponding E1B 54K protein fails to interact directly with p53 (Zantema et al., 1985b; van den Heuvel et al., 1993) . The mechanism underlying formation of the cytoplasmic body and its exact composition are uncertain. Electron micrographic analysis has indicated presence of structures similar to cytoskeletal intermediate ®laments (Zantema et al., 1985a) , but no proteins other than E1B 55K, p53 and now WT1 have been localized to this body. Of note, the cytoplasmic body is only faintly detectable in cells undergoing an acute lytic infection with adenovirus. In these cells, most of the E1B 55K protein is present within nuclear viral inclusion bodies presumed to be sites of viral DNA replication and transcription, where it is associated with the E4-34K viral product and thought to play a role in the dierential processing of viral and host mRNA (Sarnow et al., 1984; Ornelles and Shenk, 1991) . Thus, the E1B 55K cytoplasmic body appears to be a unique feature of adenovirus 5-transformed cells, in which the primary function of this oncoprotein may be the functional inactivation of host tumor suppressor proteins.
The functional consequences of the interaction between E1B 55K and WT1 are suggested by the ability of this viral oncoprotein to inhibit WT1-mediated growth inhibition. Induction of apoptosis by the WT1(7KTS) isoform in osteosarcoma cells is the most direct evidence of growth inhibition by this tumor suppressor . The observation that WT1(7KTS) fails to suppress colony formation in U2OS osteosarcoma cells expressing E1B 55K therefore con®rms the ability of this oncoprotein to inactivate WT1 function. The mechanism of WT1-mediated cell death in these cells appears to involve transcriptional repression of target genes, including epidermal growth factor receptor . Although not directly testable, it is most likely that sequestration of WT1 by E1B 55K plays a major role in its functional inactivation. Nonetheless, the inactivation of p53 by E1B 55K appears to involve both sequestration within the cytoplasmic body as well as modulation of the transactivational properties of residual nuclear p53 (Yew and Berk, 1992; Yew et al., 1994) . Developing a model system in which WT1-mediated transactivation can be measured in the presence of a stable WT1-E1B 55K interaction will be required to test any similar eects of E1B 55K on WT1. Finally, the physical association between E1B 55K and WT1 raises the possibility of a physiologically signi®cant interaction between these two proteins, most notably in the well established rodent kidney models of adenoviral transformation. Like other cellular targets of DNA tumor viruses that have proven to be critical regulators of cell growth and apoptosis, the targeting of WT1 by E1B 55K itself raises the possibility of further growth regulatory functions by WT1.
Materials and methods
Cell lines, transfections and expression constructs
BRK transformation assays were performed by calcium phosphate transfection of primary kidney cultures from 5 day old rats as originally described by van der Eb and Graham (1980) with modi®cations (Haber et al., 1992) . Stable cell lines expressing adenovirus 5 E1A (6.1 cells) and E1A plus E1B (10.2 cells) have been described elsewhere (Haber et al., 1992; Maheswaran et al., 1993 Maheswaran et al., , 1995 . To map the WT1 interaction domains, 10.2 cells were stably transfected by calcium phosphate transfection with CMV-driven, HA-tagged WT1 deletion constructs, which have been previously described . To test antibody speci®city in immuno¯uorescence experiments, E1A-immortalized BRK cells with a tetracycline-regulated WT1 construct and BRK cells expressing a temperature-sensitive p53 allele (tsp53) (provided by Dr E White, Rutgers University) were used. U2OS cells stably expressing E1B 55K were kindly provided by Dr A Fattey (Onyx Pharmaceuticals). For assays of WT1-mediated growth inhibition, cells were transfected using calcium phosphate DNA precipitation with CMV-driven constructs encoding WT1 (isoform B, encoding alternative splice I and lacking alternative splice II (KTS)), E1B 55K, or empty vector, in a 5 : 1 ratio with a drug resistance marker confering resistance to hygromycin (pCNH2). The total amount of DNA transfected was equalized using empty vector, and hygromycin resistant colonies were counted after 10 days in culture.
Antibodies, immunoprecipitations and immunodepletion analyses
Antibodies raised against dierent WT1 epitopes were used for immunoprecipitation and Western analyses. The polyclonal rabbit antibodies (WTc7 and WTc8) and the monoclonal mouse antibody (WT56), directed against the N terminus of WT1, have been described previously . The monoclonal mouse antibody DG10 (Oncogene Science) was raised against the middle third of WT1 and has been described elsewhere , and the rabbit polyclonal antibody C19 (Santa Cruz) recognizes the C terminus of WT1. The mouse monoclonal antibody 12-CA-5, which recognizes the hemagglutinin (HA) epitope was provided by Dr E Harlow (MGH). The mouse monoclonal anti-p53 antibody PAb122 was used for immunoprecipitation and immunoblotting analysis. For immunodepletion experiments, cellular extracts were cleared of p53 by repeated treatment with a mixture of antibodies PAb122, PAb421 and PAb1801 (provided by Dr E Harlow). The rat monoclonal antibody Ab1 (Oncogene Science) was used to detect E1B 55K. For immunoprecipitation experiments, cells were metabolically labeled with 300 mCi of [ 35 S]methionine overnight and proteins were extracted using 50 mM Tris pH 8.0 400 mM NaCl, 1% Nonidet P40. For immunoprecipitation-Western analysis, unlabeled lysates were extracted as above and immunoprecipitated using antibodies WTc8 and WT56 which had been covalently crosslinked to protein A-Sepharose and protein G-Sepharose respectively (Harlow and Lane, 1988) . Proteins were released from the antibody by treatment with 2% SDS/50 mM Tris, pH 6.8, at room temperature and Western blot analysis was performed according to the ECL protocol (Amersham). For gel ®ltration analysis, unlabeled cellular extracts were extracted as above and resolved on a Superose 12 FPLC column (Pharmacia) and fractions were analysed by Western blotting.
Immuno¯uorescence and confocal imaging
For immuno¯uorescence analysis, cells were grown in logarhythmic phase on coverslips and ®xed using 4% (wt/ vol) paraformaldehyde, permeabilized with 1% Nonidet P-40/10 mM glycine, and preadsorbed with 3% (wt/vol) bovine serum albumin (BSA). Coverslips were then treated with the rabbit anti-WT1 antibody WTc8 (1/100 dil), the mouse anti-p53 antibody PAb122 (1/5 dil), or the rat anti-E1B antibody Ab1 (1/500 dil), followed by either uorescein-conjugated goat anti-rabbit antibody (1/500 dil; Jackson ImmunoResearch), rhodamine or¯uorescein-conjugated goat anti mouse antibody (1/500 dil), or rhodamine-conjugated goat anti-rat antibody (1/500 dil). Cells were stained with Hoechst dye to delineate nuclei. Dual antibody staining was performed as above, with control slides stained with a single antibody to con®rm the absence of contaminating signals. Stained cells were examined using a laser confocal microscope (Biorad MRC600 imaging system attached to a Zeiss axiovert microscope) using X63 and X100 planeo¯uar objectives.
